BAROPHARM Statistics
Total Valuation
BAROPHARM has a market cap or net worth of KRW 80.17 billion. The enterprise value is 71.03 billion.
Important Dates
The next estimated earnings date is Friday, April 9, 2027.
| Earnings Date | Apr 9, 2027 |
| Ex-Dividend Date | n/a |
Share Statistics
BAROPHARM has 11.97 million shares outstanding. The number of shares has increased by 50.93% in one year.
| Current Share Class | 11.97M |
| Shares Outstanding | 11.97M |
| Shares Change (YoY) | +50.93% |
| Shares Change (QoQ) | +2.80% |
| Owned by Insiders (%) | 40.36% |
| Owned by Institutions (%) | 4.48% |
| Float | 5.00M |
Valuation Ratios
The trailing PE ratio is 42.02.
| PE Ratio | 42.02 |
| Forward PE | n/a |
| PS Ratio | 0.55 |
| PB Ratio | 2.12 |
| P/TBV Ratio | 2.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 57.47 |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | 47.24 |
| EV / Sales | 0.49 |
| EV / EBITDA | 16.99 |
| EV / EBIT | 21.76 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.25, with a Debt / Equity ratio of 0.41.
| Current Ratio | 1.25 |
| Quick Ratio | 0.79 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | 3.72 |
| Debt / FCF | n/a |
| Interest Coverage | 6.75 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 10.79% |
| Return on Capital Employed (ROCE) | 8.32% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BAROPHARM has paid 98.86 million in taxes.
| Income Tax | 98.86M |
| Effective Tax Rate | 6.17% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 3,189,502 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BAROPHARM had revenue of KRW 145.03 billion and earned 1.50 billion in profits. Earnings per share was 159.45.
| Revenue | 145.03B |
| Gross Profit | 25.38B |
| Operating Income | 3.26B |
| Pretax Income | 1.60B |
| Net Income | 1.50B |
| EBITDA | 4.18B |
| EBIT | 3.26B |
| Earnings Per Share (EPS) | 159.45 |
Full Income Statement Balance Sheet
The company has 24.70 billion in cash and 15.56 billion in debt, with a net cash position of 9.14 billion or 764.22 per share.
| Cash & Cash Equivalents | 24.70B |
| Total Debt | 15.56B |
| Net Cash | 9.14B |
| Net Cash Per Share | 764.22 |
| Equity (Book Value) | 37.74B |
| Book Value Per Share | 3,723.48 |
| Working Capital | 13.42B |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was 1.39 billion and capital expenditures -20.59 billion, giving a free cash flow of -19.19 billion.
| Operating Cash Flow | 1.39B |
| Capital Expenditures | -20.59B |
| Depreciation & Amortization | 915.89M |
| Net Borrowing | 13.65B |
| Free Cash Flow | -19.19B |
| FCF Per Share | -1,603.97 |
Full Cash Flow Statement Margins
Gross margin is 17.50%, with operating and profit margins of 2.25% and 1.04%.
| Gross Margin | 17.50% |
| Operating Margin | 2.25% |
| Pretax Margin | 1.10% |
| Profit Margin | 1.04% |
| EBITDA Margin | 2.88% |
| EBIT Margin | 2.25% |
| FCF Margin | n/a |
Dividends & Yields
BAROPHARM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -50.93% |
| Shareholder Yield | -50.93% |
| Earnings Yield | 2.38% |
| FCF Yield | -23.94% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BAROPHARM has an Altman Z-Score of 1.27 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.27 |
| Piotroski F-Score | 3 |